ClinicalTrials.gg

Program

HL-1186

A development code.

Its studies are mostly in Pain, Postoperative · Neuralgia, Postherpetic · Neuralgia, led by 2 companies.

Furthest: phase 3, since Aug 11, 20257 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Yidian Pharmaceutical Technology Development55 open or runningphase 2since Aug 11, 2025Mar 24, 2025Jun 2027phase 2 · NCT07758920
Shanghai Huilun Pharmaceutical22 open or runningphase 3since Apr 26, 2026Apr 26, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2025First study: phase 1 study in Healthy ParticipantsNew to Shanghai Yidian Pharmaceutical Technology DevelopmentShanghai Yidian Pharmaceutical Technology Development · NCT06912295 · 76 planned · China
  2. Aug 11, 20252 phase 2 studiesShanghai Yidian Pharmaceutical Technology Development · NCT07147049, NCT07159243
  3. Dec 16, 2025Phase 2 study in Moderate to Severe Acute Postoperative PainShanghai Yidian Pharmaceutical Technology Development · NCT07311369 · 40 planned · China
  4. Apr 26, 2026Shanghai Huilun Pharmaceutical's first study: phase 3 study in Pain, PostoperativeNew to Shanghai Huilun PharmaceuticalShanghai Huilun Pharmaceutical · NCT07699601 · 330 planned · China
  5. Jul 12, 2026Phase 3 study in Pain, PostoperativeShanghai Huilun Pharmaceutical · NCT07709598 · 330 planned · China
  6. Aug 2, 2026Phase 2 study in Neuralgia, PostherpeticShanghai Yidian Pharmaceutical Technology Development · NCT07758920 · 200 planned · China

Ahead

  1. Jun 2027Primary completion: phase 2 study in Neuralgia, PostherpeticShanghai Yidian Pharmaceutical Technology Development · NCT07758920

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07758920Neuralgia, Postherpetic · China2RecruitingShanghai Yidian Pharmaceutical Technology DevelopmentJun 2027200
NCT07709598Pain, Postoperative · China3RecruitingShanghai Huilun PharmaceuticalOct 2026330
NCT07699601Pain, Postoperative · China3RecruitingShanghai Huilun PharmaceuticalOct 2026330
NCT07311369Moderate to Severe Acute Postoperative Pain · China2RecruitingShanghai Yidian Pharmaceutical Technology DevelopmentFeb 202640
NCT07159243Diabetic Peripheral Neuropathic Pain2Not yet recruitingShanghai Yidian Pharmaceutical Technology DevelopmentOct 2026180
NCT07147049Moderate to Severe Acute Postoperative Pain · China2RecruitingShanghai Yidian Pharmaceutical Technology DevelopmentDec 202572
NCT06912295Healthy Participants · China1RecruitingShanghai Yidian Pharmaceutical Technology DevelopmentAug 30, 202576

How it is read

Names in the registry

  • “HL-1186”, 8 entries

Codes read as this program: HL1186.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.